DK2547679T3 - 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonan-derivater og deres anvendelse som antagonister eller inverse agonister af ghrelin-receptoren - Google Patents
2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonan-derivater og deres anvendelse som antagonister eller inverse agonister af ghrelin-receptoren Download PDFInfo
- Publication number
- DK2547679T3 DK2547679T3 DK11713083.1T DK11713083T DK2547679T3 DK 2547679 T3 DK2547679 T3 DK 2547679T3 DK 11713083 T DK11713083 T DK 11713083T DK 2547679 T3 DK2547679 T3 DK 2547679T3
- Authority
- DK
- Denmark
- Prior art keywords
- dihydro
- diazaspiro
- inden
- acetyl
- nonane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1. Forbindelse med formel (I)
(l) j hvor: R1 er -L1-R1, phenyl eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor phenylet eller det 5- til 6-leddede heteroaryl eventuelt er kondenseret til et (C4-C7)cycloalkyl, (C5-C6)cycloalkenyl, phenyl, mættet eller delvist umættet 5-til 6-leddet heterocyclyl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor det eventuelt kondenserede phenyl og det eventuelt kondenserede 5- til 6-leddede heteroaryl eventuelt er substitueret med 1 til 3 substitu-enter udvalgt fra halogen, hydroxy, oxo, cyano, (C-i-C3)alkyl, halogensubstitueret (CrC3)alkyl, (CrC3)alkoxy, halogen-substitueret (CrC3)alkoxy, (CrC3)alkyl-S(0),-, (C3-C6)cycloalkyl, (C3-C6)cycloalkoxy, -(C0- C3)alkylNRxRy, -(C0-C3)alkylNRxC(O)Ry og -(C0-C3)alkylC(O)NRxRy; R1 er phenyl eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor phenylet eller det 5- til 6-leddede heteroaryl eventuelt er kondenseret til et (C4-C7)cycloalkyl, (C5-C6)cycloalkenyl, phenyl, mættet eller delvist umættet 5- til 6-leddet heterocyclyl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor det eventuelt kondenserede phenyl og det eventuelt kondenserede 5- til 6-leddede heteroaryl eventuelt er substitueret med 1 til 3 substitu-enter udvalgt fra halogen, hydroxy, oxo, cyano, (CrC3)alkyl, halogen-substitueret (CrC3)alkyl, (CrC3)alkoxy, halogen-substitueret (CrC3)alkoxy, (CrC3)alkyl- S(0)n-, (C3-C6)cycloalkyl, (C3-C6)cycloalkoxy, -(C0-C3)alkylNRxRy, -(C0-C3)alkylNRxC(0)Ry og -(C0-C3)alkylC(O)NRxRy; L1 er O, S, NH, N(Ci-C3)alkyl eller (Ci-C3)alkylen; Ra ved hver forekomst uafhængigt er udvalgt fra hydrogen, (CrC3)alkyl og halogen; Z, Z1 og Z2 hver især uafhængigt er N eller CH eventuelt substitueret med halogen, (CrC3)alkoxy eller (CrC3)alkyl; L er en direkte binding O, S, NH, N(CrC3)alkyl eller (CrC3)alkylen; R2 er hydrogen, halogen, cyano, (CrC6)alkyl, (C3-C6)cycloalkyl, phenyl, mættet eller delvist umættet 5- til 6-leddet heterocyclyl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, eller 5-til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor (CrC6)alkylet, (C3-C6)cycloalkylet, phenylet, det mættede eller delvist umættede 5- til 6-leddede heterocyclyl, eller det 5- til 6-leddede heteroaryl eventuelt er substitueret med 1 til 3 substi-tuenter uafhængigt udvalgt fra gruppen bestående af halogen, hydroxy, cyano, (CrC3)alkyl, halogen-substitueret (C-|-C3)alkyl, (CrC3)alkoxy, halogensubstitueret (CrC3)alkoxy, (C-|-C3)alkyl-S(0)n-, (C3-C6)cycloalkyl, (C3-C6)cycloalkoxy, -(C0-C3)alkylNRxRy, -(C0-C3)alkylNRxC(O)Ry og -(C0-C3)alkylC(0)NRxRy; forudsat at hvis L er O, S, NH eller N(CrC3)alkyl, så er R2 ikke halogen; n ved hver forekomst uafhængigt er 0, 1 eller 2; og Rx og Ry ved hver forekomst uafhængigt er udvalgt fra hydrogen og (Cr C6)alkyl, hvor (CrC6)alkylet eventuelt er afbrudt af en eller to grupper uafhængigt udvalgt fra NH, N(CrC3)alkyl, O og S, og eventuelt er substitueret med 1 til 4 halogener; eller Rx og Ry sammen er et (C2-C6)alkylen, som eventuelt er afbrudt af en eller to grupper uafhængigt udvalgt fra NH, N(Cr C3)alkyl, O og S; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge kravl, hvor: R1 er phenyl eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor phenylet eller det 5- til 6-leddede heteroaryl eventuelt er kondenseret til et (C4-C7)cycloalkyl, (C5-C6)cycloalkenyl, phenyl, mættet eller delvist umættet 5-til 6-leddet heterocyclyl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, eller et 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor det eventuelt kondenserede phenyl og det eventuelt kondenserede 5- til 6-leddede heteroaryl eventuelt er substitueret med 1 til 3 substitu-enter udvalgt fra halogen, hydroxy, oxo, cyano, (CrC3)alkyl, halogensubstitueret (CrC3)alkyl, (CrC3)alkoxy, halogen-substitueret (CrC3)alkoxy, (CrC3)alkyl-S(0)n-, (C3-C6)cycloalkyl, (C3-C6)cycloalkoxy, -(C0-C3)alkyl-NRxRy, -(C0-C3)alkyl-NRxC(O)Ry og -(C0-C3)alkyl-C(O)NRxRy; Ra ved hver forekomst uafhængigt er udvalgt fra hydrogen, (CrC3)alkyl og halogen; Z, Z1 og Z2 hver især uafhængigt er N eller CH eventuelt substitueret med halogen, (CrC3)alkoxy eller (CrC3)alkyl; L er en direkte binding, O, S, NH, N(CrC3)alkyl eller (CrC3)alkylen; R2 er hydrogen, halogen, cyano, (C-rC6)alkyl, (C3-C6)cycloalkyl, phenyl, mættet eller delvist umættet 5- til 6-leddet heterocyclyl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, eller 5- til 6-leddet heteroaryl indeholdende 1 til 4 heteroatomer, som hver især uafhængigt er udvalgt fra N, O eller S, hvor (C-|-C6)alkylet, (C3-C6)cycloalkylet, phenylet, det mættede eller delvist umættede 5- til 6-leddede heterocyclyl eller 5- til 6-leddede heteroaryl eventuelt er substitueret med 1 til 3 substituenter uafhængigt udvalgt fra gruppen bestående af halogen, hydroxy, cyano, (CrC3)alkyl, halogen-substitueret (CrC3)alkyl, (CrC3)alkoxy, halogen-substitueret (CrC3)alkoxy, (C-|-C3)alkyl-S(0)n-, (C3-C6)cycloalkyl, (C3-C6)cycloalkoxy, -(C0-C3)alkylNRxRy, -(C0-C3)alkylNRxC(O)Ry og -(C0-C3)alkylC(0)NRxRy; forudsat at hvis L er O, S, NH eller N(CrC3)alkyl, så er R2 ikke halogen; n ved hver forekomst uafhængigt er 0, 1 eller 2; og Rx og Ry ved hver forekomst uafhængigt er udvalgt fra hydrogen og (Cr C6)alkyl, hvor (CrC6)alkylet eventuelt er afbrudt af en eller to grupper, uafhængigt udvalgt fra NH, N(CrC3)alkyl, O og S, og eventuelt er substitueret med 1 til 4 halogener; eller Rx og Ry sammen er et (C2-C6)alkylen, som eventuelt er afbrudt af en eller to grupper uafhængigt udvalgt fra NH, N(Cr C3)alkyl, O og S; eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 2, hvor: R1 er phenyl, naphthyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, thiazolyl, oxazolyl, thiazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridinyl, 2,3-dihydrofurano[3,2-b]pyridinyl, indolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, [1,2,4]triazolo[4,3-a]pyridin, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyra-zolo[1,5-a]pyridinyl, imidazo[1,2-b][1,2,4]triazinyl, 1 H-pyrazolo[3,4-b]pyridinyl, 4.5.6.7- tetrahydropyrazolo[1,5-a]pyridinyl, imidazo[2,1 -b][ 1,3,4]thiadiazolyl, 1 H-indazolyl, pyridazinyl, oxadiazolyl eller imidazo[1,2-a]pyridinyl; imidazo[1,2-b]pyridazinyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridinyl (hver især eventuelt substitueret med 1 til 3 substituenter uafhængigt udvalgt fra fluor, chlor, (Cr C3)alkyl, (CrC3)alkoxy, trifluormethyl, trifluormethoxy, cyano, cyclopropyl, -C(0)NRxRy og -(C0-Ci)alkylNHC(O)CH3; eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 3, hvor: R1 er phenyl, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyrazolo[1,5-a]pyridinyl, 4.5.6.7- tetrahydropyrazolo[1,5-a]pyridinyl, imidazo[2,1 -b][ 1,3,4]thiadiazolyl, 1 H-indazolyl, pyridazinyl, oxadiazolyl eller imidazo[1,2-a]pyridinyl, imidazo[1,2-b]pyridazinyl, 1 H-pyrazolo[3,4-b]pyridinyl, imidazo[1,2-b]pyridazinyl, 2,3-dihydro[1,4]dioxino[2,3-b]pyridinyl: hver især eventuelt substitueret med 1 til 3 substituenter uafhængigt udvalgt fra methyl, methoxy, cyano, cyclopropyl, -C(0)NH2 og -NHC(0)CH3; Ra ved hver forekomst er hydrogen; og Z, Z1 og Z2 hver især er CH; eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge krav 2, hvor L er en direkte binding; og R2 er hydrogen, phenyl, pyrimidinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, triazinyl eller pyrazinyl; hver især eventuelt substitueret med 1 til 3 substituenter uafhængigt udvalgt fra methyl, trifluormethyl, ethyl, methoxy, cyano eller -C(0)NH2; eller et farmaceutisk acceptabelt salt deraf.
6. Forbindelse ifølge krav 2 med formel (IA)
(IA) eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 6, hvor R1 er phenyl, naphthyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, thiazolyl, oxazolyl, thiazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, 2,3- dihydrobenzofuranyl, chromanyl, 3,4-dihydro-2FI-pyrano[3,2-b]pyridinyl, 2,3-dihydrofurano[3,2-b]pyridinyl, indolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, [1,2,4]triazolo[4,3-a]pyridin, imidazo[2,1-b][1,3]thiazolyl, pyridinyl, pyra- zolo[1,5-a]pyridinyl, imidazo[1,2-b][1,2,4]triazinyl, 1 FI-pyrazolo[3,4-b]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, imidazo[2,1 -b][ 1,3,4]thiadiazolyl, 1 H-indazolyl, imidazo[1,2-b]pyridazinyl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl eller imidazo[1,2-a]pyridinyl; hver især eventuelt substitueret med 1 til 3 sub-stituenter uafhængigt udvalgt fra fluor, chlor, (CrC3)alkyl, (CrC3)alkoxy, trifluormethyl, trifluormethoxy, cyano, cyclopropyl, -C(0)NFl2 og -NFIC(0)CFI3; eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge krav 7, hvor: R2 er phenyl, pyrimidinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, triazinyl eller pyrazinyl hver især eventuelt substitueret med 1 til 3 substituenter uafhængigt udvalgt fra methyl, ethyl, methoxy, cyano eller -C(0)NFl2; og L er en direkte binding eller O; eller et farmaceutisk acceptabelt salt deraf.
9. Forbindelse ifølge krav 8, hvor R2 er phenyl, pyrimidinyl, triazolyl, thiazolyl, pyridinyl, oxazolyl, pyrazolyl eller pyrazinyl; hver især eventuelt substitueret med 1 til 3 substituenter uafhængigt udvalgt fra methyl, ethyl, methoxy, cyano eller -C(0)NFl2; og L er en direkte binding; eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge krav 1 udvalgt fra gruppen bestående af: 5-[1-{7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrazin-2-carboxamid; 5-[1-{7-[(7-methylimidazo[1,2-a]pyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrazin-2-carboxamid; 5- {1-[7-(imidazo[1,2-a]pyridin-2-ylacetyl)-2,7-diazaspiro[3.5]non-2-yl]-2,3-dihydro-1 H-inden-5-yl}pyrazin-2-carboxamid; 6- [1-{7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrimidin-4-carboxamid; 5-[1-{7-[(5-cycl°propylpyndin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; 5- [1 -{7-[(2-methylimidazo[2,1 -b][1,3,4]thiadiazol-6-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; 6- [1-{7-[(7-methylimidazo[1,2-a]pyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrimidin-4-carboxamid; 5- [1-{7-[(5-ethylpyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrazin-2-carboxamid; 6- [1-{7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]nicotinamid; 7- [(4-methoxyphenyl)acetyl]-2-(5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl)- 2.7- diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 3-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)-1 H-indazol; 7-[(4-methoxyphenyl)acetyl]-2-[5-(2-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-methoxyphenyl)acetyl]-2-[5-(5-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(1,3-thiazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methyl-1,3-thiazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1 -b][1,3,4]thiadiazol-6-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-(5-phenoxy-2,3-dihydro-1 H-inden-1-yl)- 2.7- diazaspiro[3.5]nonan; 7-[(4-methoxyphenyl)acetyl]-2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetyl]-2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methoxypyridin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(2-methylpyridin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 2-(1-{7-[(5-methoxypyndin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl)isonicotinonitril; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methylpyridin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methoxypyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(6-methoxypyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(4-methylpyridin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-(5-pyrazin-2-yl-2,3-dihydro-1 H-inden-1-yl)- 2.7- diazaspiro[3.5]nonan; 2-[5-(4,6-dimethylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(6-methylpyridin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 2-[5-(5-ethylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 2-[5-(6-ethylpyri midin-4-yl)-2,3-di hydro-1 H-inden-1-yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 2-(2-{2-[5-(6-ethylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-5-methoxybenzonitril; 6- [1-{7-[(5-methoxypyndin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrimidin-4-carbonitril; 7- [(4-methoxyphenyl)acetyl]-2-[5-(1,3-oxazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]- 2.7- diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-pyrimidin-4-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-cyclopropylpyridin-2-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(1,3-oxazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-(5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl)-7-{[4-(trifluormethyl)phenyl] acetyl}-2,7-diazaspiro[3.5]nonan; 5-methoxy-2-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethoxy)benzonitril; 2-[2,3-dihydro-1 H-inden-1-yl]-7-[(4-methoxyphenyl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-[(5-cyclopropylpyridin-2-yl)acetyl]-2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-[5-(4,6-dimethylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 5- methoxy-2-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzonitril; 7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2-[5-(5-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 2-[5-(2,6-dimethylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 6- [1-{7-[(7-methylimidazo[1,2-a]pyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrimidin-4-carbonitril; N-[5-methoxy-2-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]- 2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)phenyl]acetamid; 7- [(2,3-dimethylimidazo[2,1-b][1,3]thiazol-6-yl)acetyl]-2-[5-(6-methylpyrimidin- 4-yl)-2,3-dihyd ro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(1 -ethyl-1 H-pyrazol-3-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 1 -methyl-3-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-1 H-pyrazolo[3,4-b]pyridin; 1 -ethyl-3-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-1 H-pyrazolo[3,4-b]pyridin; 7-[(1 -phenyl-1 H-imidazol-4-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-{[5-(difluormethyl)pyridin-2-yl]acetyl}-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(3-methyl-1 H-pyrazol-5-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 6-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)imidazo[1,2-b][1,2,4]triazin; 6- [1-{7-[(5-cyclopropylpyndin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyrimidin-4-carbonitril; 7- [(5-methoxypyridin-2-yl)acetyl]-2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 6-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; 6- (2-{2-[5-(2-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; 7- [(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)acetyl]-2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methylpyridin-2-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]- 2,7-diazaspiro[3.5]nonan; 2-[5-(1 -methyl-1 H-pyrazol-3-yl)-2,3-dihydro-1 H-inden-1 -yl]-7-[(5-methylpyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(2-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)imidazo[1,2-a]pyridin; 7-[(5-methylpyridin-2-yl)acetyl]-2-[5-(1,3-thiazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methylpyridin-2-yl)acetyl]-2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(1-methyl-1 H-pyrazol-3-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; N-[5-methoxy-2-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)phenyl]acetamid; 2-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)imidazo[1,2-a]pyridin; 6- (2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; 7- [(5-methoxypyridin-2-yl)acetyl]-2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methylpyridin-2-yl)acetyl]-2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 6- (2-{2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; 7- [(5-methoxypyridin-2-yl)acetyl]-2-[5-(6-methoxypyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-[5-(5-ethylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(4-methoxyphenyl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-methyl-2-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)imidazo[1,2-a]pyridin; 7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2-[5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)acetyl]-2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 4- [1-{7-[(7-methylimidazo[1,2-a]pyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]benzamid; 5- [1-{7-[(5-rnethoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carbonitril; 4-[1-{7-[(5-ethylpyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]benzamid; 4-[1-{7-[(5-rnethoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]benzamid; 4-{1-[7-(imidazo[1,2-a]pyridin-2-ylacetyl)-2,7-diazaspiro[3.5]non-2-yl]-2,3-dihydro-1 H-inden-5-yl}benzamid; 7-[(4-cycl°propylphenyl)acetyl]-2-(5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl)-2,7-diazaspiro[3.5]nonan; 7-[(4-cyclopropylphenyl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]- 2.7- diazaspiro[3.5]nonan; 7-[(5-ethylpyridin-2-yl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]- 2.7- diazaspiro[3.5]nonan; 7-[(5-methylpyridin-2-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-ethylpyridin-2-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-methylphenyl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-ethylphenyl)acetyl]-2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-[5-(2,6-dimethylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 2-{2-oxo-2-[2-(5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl)-2,7-diazaspiro[3.5]non-7-yl]ethyl}pyrazolo[1,5-a]pyridin; 2-{2-oxo-2-[2-(5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl)-2,7-diazaspiro[3.5]non-7-yl]ethyl}-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin; 7-methyl-2-(2-oxo-2-{2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]- 2,7-diazaspiro[3.5]non-7-yl}ethyl)imidazo[1,2-a]pyridin; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-methoxyphenyl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1 -b][1,3]thiazol-6-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)- 2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-ethoxypyridin-2-yl)acetyl]-2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; N-[5-methoxy-2-(2-oxo-2-{2-[5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)phenyl]acetamid; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(1 H-1,2,4-triazol-1 -yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(5-methyl-1,3,4-thiadiazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 5-methyl-2-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)benzamid; 5-methoxy-2-(2-oxo-2-{2-[5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)benzamid; 5-methoxy-2-(2-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzamid; 5-methoxy-2-(3-{2-[5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-3-oxopropyl)benzamid; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(4-methyl-1 H-pyrazol-1-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-methoxyphenyl)acetyl]-2-[5-(4-methyl-1 H-pyrazol-1 -yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[5-(1 H-pyrazol-1 -yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 5-{1-[7-(2,3-dihydro[1,4]dioxino[2,3-b]pyridin-6-ylacetyl)-2,7-diazaspiro[3.5]non-2-yl]-2,3-dihydro-1 H-inden-5-yl}pyridin-2-carboxamid; 5-[1-{7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; 5-[1-{7-[(5-methylpyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; 5-[1 -{7-[(2-methylimidazo[2,1 -b][1,3]thiazol-6-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; 5-{1-[7-(imidazo[1,2-a]pyridin-2-ylacetyl)-2,7-diazaspiro[3.5]non-2-yl]-2,3-dihydro-1 H-inden-5-yl}pyridin-2-carboxamid; og 5-[1-{7-[(7-methylimidazo[1,2-a]pyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]non-2-yl}-2,3-dihydro-1 H-inden-5-yl]pyridin-2-carboxamid; eller et farmaceutisk acceptabelt salt deraf.
11. Forbindelse ifølge krav 6 udvalgt fra gruppen bestående af 7-[(2-methylimidazo[2,1 -b][1,3]thiazol-6-yl)acetyl]-2-[(1 R)-5-pyrimidi n-2-yl- 2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(4-methoxyphenyl)acetyl]-2-[(1 R)-5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[(1 R)-5-(1,3-thiazol-2-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 2-[(1 R)-5-(5-ethylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[(1 R)-5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[(1 R)-5-(5-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-ethylpyridin-2-yl)acetyl]-2-[(1 R)-5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 - yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methoxypyridin-2-yl)acetyl]-2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 7-[(5-methylpyridin-2-yl)acetyl]-2-[(1 R)-5-(2H-1,2,3-triazol-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-[(1 R)-5-(2,6-dimethylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-7-[(5-methoxypyridin-2-yl)acetyl]-2,7-diazaspiro[3.5]nonan; 7-[(2-methylimidazo[2,1 -b][1,3]thiazol-6-yl)acetyl]-2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 6- (2-{2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; 5-{(1 R)-1 -[7-(2,3-dihydro[1,4]dioxino[2,3-b]pyridin-6-ylacetyl)-2,7-diazaspiro[3.5]non-2-yl]-2,3-dihydro-1 H-inden-5-yl}pyridin-2-carboxamid; 7- [(5-methoxypyridin-2-yl)acetyl]-2-[(1 R)-5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan; 2-(2-{2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)imidazo[1,2-a]pyridin; 7-[(2-methylimidazo[2,1 -b][1,3,4]thiadiazol-6-yl)acetyl]-2-[(1 R)-5-(6- methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1-yl]-2,7-diazaspiro[3.5]nonan; 5-methoxy-2-(2-oxo-2-{2-[(1 R)-5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]- 2.7- diazaspiro[3.5]non-7-yl}ethyl)benzamid; 5- methoxy-2-(2-{2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzamid; N-[5-methoxy-2-(2-oxo-2-{2-[(1 R)-5-pyrimidin-2-yl-2,3-dihydro-1 H-inden-1 -yl]- 2.7- diazaspiro[3.5]non-7-yl}ethyl)phenyl]acetamid; og 6- (2-{2-[(1 R)-5-(2-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin; eller et farmaceutisk acceptabelt salt deraf.
12. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1 til 11 eller et farmaceutisk acceptabelt salt deraf og et farmaceutisk acceptabelt hjælpestof, fortyndingsmiddel eller bæremiddel.
13. Sammensætning ifølge krav 12, hvor forbindelsen eller det farmaceutisk acceptable salt deraf er til stede i en terapeutisk virksom mængde.
14. Forbindelse ifølge krav 1, som er 7-[(2-methylimidazo[2,1 -b][1,3]thiazol-6-yl)acetyl]-2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden-1 -yl]-2,7-diazaspiro[3.5]nonan, eller et farmaceutisk acceptabelt salt deraf.
15. Forbindelse ifølge krav 1, som har strukturen
16. Forbindelse ifølge krav 1, som er 6-(2-{2-[(1 R)-5-(2-methylpyrimidin-4-yl)- 2,3-dihydro-1 FI-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)-2,3-dihydro[1,4]dioxino[2,3-b]pyridin, eller et farmaceutisk acceptabelt salt deraf.
17. Forbindelse ifølge krav 1, som er 7-[(2-methylimidazo[2,1 -b][1,3,4]thiadiazol-6-yl)acetyl]-2-[(1 R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro- 1 FI-inden-1-yl]-2,7-diazaspiro[3.5]nonan, eller et farmaceutisk acceptabelt salt deraf.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31552210P | 2010-03-19 | 2010-03-19 | |
US201161444401P | 2011-02-18 | 2011-02-18 | |
PCT/IB2011/051035 WO2011114271A1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2547679T3 true DK2547679T3 (da) | 2016-01-11 |
Family
ID=44647714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11713083.1T DK2547679T3 (da) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonan-derivater og deres anvendelse som antagonister eller inverse agonister af ghrelin-receptoren |
Country Status (26)
Country | Link |
---|---|
US (2) | US8609680B2 (da) |
EP (1) | EP2547679B1 (da) |
JP (1) | JP5496409B2 (da) |
KR (1) | KR101455917B1 (da) |
CN (1) | CN102939290B (da) |
AR (1) | AR080688A1 (da) |
AU (1) | AU2011228699B2 (da) |
BR (1) | BR112012023664B1 (da) |
CA (1) | CA2792234C (da) |
CY (1) | CY1118721T1 (da) |
DK (1) | DK2547679T3 (da) |
ES (1) | ES2557895T3 (da) |
HK (1) | HK1182094A1 (da) |
HR (1) | HRP20151232T1 (da) |
HU (1) | HUE025774T2 (da) |
IL (1) | IL221952A (da) |
ME (1) | ME02330B (da) |
MX (1) | MX2012010772A (da) |
PL (1) | PL2547679T3 (da) |
PT (1) | PT2547679E (da) |
RS (1) | RS54383B1 (da) |
RU (1) | RU2524341C2 (da) |
SG (1) | SG183812A1 (da) |
SI (1) | SI2547679T1 (da) |
TW (1) | TWI410423B (da) |
WO (1) | WO2011114271A1 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201407387UA (en) * | 2012-06-04 | 2014-12-30 | Pfizer | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
AU2013276617B9 (en) | 2012-06-13 | 2018-03-29 | F. Hoffmann-La Roche Ag | New diazaspirocycloalkane and azaspirocycloalkane |
RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
PT3074400T (pt) | 2013-11-26 | 2018-01-22 | Hoffmann La Roche | Novo octahidro-ciclobuta [1,2-c;3,4-c']dipirrol-2-il |
CN106103439B (zh) | 2014-03-17 | 2019-03-08 | 瑞敏德股份有限公司 | 2,7-二氮杂螺[3.5]壬烷化合物 |
EP3590939A1 (en) | 2014-03-26 | 2020-01-08 | F. Hoffmann-La Roche AG | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
CN104610143A (zh) * | 2015-02-12 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
AU2016316717B2 (en) | 2015-09-04 | 2021-02-18 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
CN107922415B (zh) | 2015-09-24 | 2022-04-15 | 豪夫迈·罗氏有限公司 | 新的作为双重atx/ca抑制剂的二环化合物 |
MX2018002217A (es) | 2015-09-24 | 2018-03-23 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). |
JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | デュアルatx/ca阻害剤としての新規な二環式化合物 |
KR20180054635A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서 이환형 화합물 |
KR20180096406A (ko) | 2017-02-21 | 2018-08-29 | 엘지전자 주식회사 | 냉장고 |
BR112019019017A2 (pt) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca |
CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
WO2019023575A1 (en) * | 2017-07-28 | 2019-01-31 | Chemocentryx, Inc. | IMMUNOMODULATORY COMPOUNDS |
CN108588215A (zh) * | 2018-05-03 | 2018-09-28 | 成都中创清科医学检验所有限公司 | 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法 |
CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
CN110256349B (zh) * | 2019-04-23 | 2020-09-08 | 苏州大学 | 多取代吡唑及其制备方法 |
CN110172062B (zh) * | 2019-06-21 | 2022-01-07 | 南京药石科技股份有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
KR20220001745U (ko) | 2021-01-06 | 2022-07-13 | 성보라 | 자동차시트 후면 보호용 보조커버 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
ES2246481T3 (es) | 2002-02-27 | 2006-02-16 | Pfizer Products Inc. | Inhibidores de la acc. |
SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
JP2009521452A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置 |
NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
MX2009002918A (es) * | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
US7638526B2 (en) * | 2006-09-15 | 2009-12-29 | Schering Corporation | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
KR20090083956A (ko) | 2006-11-29 | 2009-08-04 | 화이자 프로덕츠 인크. | 스피로케톤 아세틸-CoA 카르복실라제 억제제 |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
AU2009261248A1 (en) * | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
BRPI0918841B8 (pt) | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
GEP20156239B (en) | 2009-03-11 | 2015-01-26 | Pfizer | Benzofuranyl derivatives used as glucokinase inhibitors |
US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
TW201038572A (en) * | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
WO2010141817A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
EP2438051A1 (en) | 2009-06-05 | 2012-04-11 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2011
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/ru not_active IP Right Cessation
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/me unknown
- 2011-03-11 RS RS20150808A patent/RS54383B1/en unknown
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/da active
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/es active IP Right Grant
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/ko active IP Right Grant
- 2011-03-11 SI SI201130664T patent/SI2547679T1/sl unknown
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/es active Active
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/pt not_active IP Right Cessation
- 2011-03-11 PT PT117130831T patent/PT2547679E/pt unknown
- 2011-03-11 PL PL11713083T patent/PL2547679T3/pl unknown
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/zh not_active Expired - Fee Related
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en active Application Filing
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/ja not_active Expired - Fee Related
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-16 TW TW100109022A patent/TWI410423B/zh not_active IP Right Cessation
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-18 AR ARP110100888A patent/AR080688A1/es not_active Application Discontinuation
-
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
-
2013
- 2013-08-08 HK HK13109302.9A patent/HK1182094A1/zh not_active IP Right Cessation
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
-
2015
- 2015-11-16 HR HRP20151232TT patent/HRP20151232T1/hr unknown
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2547679T3 (da) | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonan-derivater og deres anvendelse som antagonister eller inverse agonister af ghrelin-receptoren | |
CA2811033C (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
US8993586B2 (en) | N1/N2-lactam acetyl-CoA carboxylase inhibitors | |
AU2010317501B2 (en) | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | |
TWI464171B (zh) | 經取代之乙醯輔酶a羧化酶抑制劑類 | |
OA16631A (en) | Pyrazolospiroketone derivatives for use as ACETYL-COA Carboxylase inhibitors |